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ABSTRACT 
Background: In population-based studies, the genetic variability of the APOE E alleles have 
been associated with health outcomes. Health problems are common in subjects with obesity. 
This study explored associations between the APOE E alleles and comorbidity in subjects with 
morbid obesity.   
Methods: The study included consecutive subjects referred for evaluation of bariatric surgery 
with morbid obesity (defined as BMI > 40 or > 35 kg/m2 with complications related to obesity). 
The subjects followed a conservative weight loss program for six months before surgery and had 
a follow-up visit 12 months after surgery. Demographic data and a set psychosomatic scores 
(musculoskeletal pain, WHO-5 Well-Being Index, Rosenberg Self-Esteem Scale, Hopkins 
Symptom Check-list 10; Epworth Sleepiness Scale, and Fatigue Severity Scale) were collected, 
and blood samples were analysed for haematological and biochemical parameters and APOE 
alleles.  
Results: One hundred and forty subjects (men/women: 32 (23%)/108 (77%) with mean age 43.0 
(SD 8.7) years and BMI 42.1 (SD 3.8) kg/m2 were included. One hundred and eight and 92 
subjects had data after conservative treatment and 12 months after surgery, respectively. The 
prevalence of the APOE alleles were: E2E2: 1 (0.7%), E2E3: 13 (9.3%), E2E4: 4 (2.9%), E3E3: 
71 (50.7%), E3E4: 47 (33.6%), and E4E4: 4 (2.9%). The prevalence rates were as anticipated in a 
Norwegian population. The weight loss during conservative treatment and after bariatric surgery 
was independent of E allele variability. E2 was associated with a significant or clear trend toward 
improvement of all psychosomatic disorders. There was a significant fall in CRP during the two 
treatment periods with weight loss. E2 and E4 were significantly associated with high and low 
CRP, respectively, but no associations were seen between CRP and comorbidity.  
Conclusions: The most marked finding was the association between E2 and improvement of all 
psychosomatic disorders. The positive and negative associations between CRP and E2 and E4, 
respectively, could indicate effects on inflammation and immunological reactions. 
Keywords: APOE; Comorbidity; CRP; Inflammation; Obesity; Psychosomatic disorders.  
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Background 
The human APOE gene has three common allelic variants E2, E3, and E4 encoded on 
chromosome 19. Depending on the genetic variability, the gene has been ascribed significant 
positive and negative health effects such as longevity and shortened lifespan, neurological and 
psychosomatic disorders, cognitive decline and Alzheimer disease, altered lipoprotein profile, 
atherosclerosis and cardiovascular disease, type II diabetes, changes in the immune response, 
oxidative stress, quality of life, physical activity, and obesity [1-4]. At large, E4 has been ascribed 
unfavourable health outcomes and E2 health-promoting effects [1, 5-11]. 
 Obesity is a global health challenge due to the high prevalence of serious comorbidity [12-
14]. The comorbidity of obesity (metabolic syndrome and type II diabetes, cardiovascular disease, 
musculoskeletal disorders and cancer) coincide in part with disorders associated with variability 
of the APOE isoforms. The associations between biomarkers and disease in subjects with obesity 
are, however, not always as expected, as exemplified by the protective effect of obesity on the 
outcome of cardiovascular disease (the obesity paradox) [15]. Except for a possible association 
between E4 and obesity, little is known about associations between APOE variability and 
morbidity in subjects with obesity [2, 3]. 
The paramount aim of this study was to explore associations between the APOE E alleles 
and psychosomatic disorders and inflammatory markers in subjects with morbid obesity. The 
study aimed primarily at exploring the prevalence of APOE E4 in subjects with morbid obesity 
and the effect of E4 on conservative and surgically induced weight reduction. Secondary aims 
were to study the effects of all APOE alleles on weight and weight reduction, comorbidity and 
biochemical biomarkers. The associations between comorbidity and inflammatory markers and 
the APOE alleles were performed as post hoc analyses.  
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Methods 
Study design 
The data is a subset of the prospective cohort study in subjects with morbid obesity, the MO-
BiPS study, (Morbid Obesity – Bio-Psycho-Social disorders) referred for evaluation of bariatric 
surgery at Innlandet Hospital Trust, Gjøvik, Norway [16-18].  After inclusion and before surgery, 
the participants followed a conservative weight-loss program for six months with dietary advice 
and increased physical activity (the first treatment period). A follow-up visit was scheduled 12 
months after surgery (the second treatment period). 
Subjects 
Consecutive subjects aged 18 - 65 years with morbid obesity (defined as BMI ≥ 40 kg/m2 or ≥35 
kg/m2 with complications related to obesity) were from December 2012 to September 2014 
included in the study. The doctors were responsible for the medical history and the physical 
examination, and decided necessary supplementary examinations. Blood samples were collected. 
The patints filled in paper-based questionnaires. Subjects with a somatic disease or psychiatric 
disorders in need of treatment and judged as unrelated to obesity, were excluded. A study nurse 
was responsible for the care of the patients and most of the practical work. 
Variables 
The following variables were collected at inclusion: 
 Gender, age (years), body mass index (BMI, kg/m2), smoking habits (never / previously / 
daily smokers), all regular use of drugs and present or previous somatic disorders including 
hypertension and diabetes (yes / no).  
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 Blood samples were analysed for standard haematological and biochemical variables, 
inflammatory markers [C-reactive protein (CRP), Interleukin-6 (Il-6) and Tumor Necrosis 
Factor (TNF)] and APOE genotype.  
 Two questions assessed physical activity: Easy activity (not sweaty/breathless): none; <1 h; 1–2 h; 
≥3 h/week (score 0–3). Strenuous activity (sweaty/breathless): none; <1 h; 1–2 h; ≥3 h/week (score 0, 
3, 4, 5). Sum score physical activity 0–8. 
 Musculoskeletal pain from six parts of the body (score 0–12).  
 WHO-5 Well-Being Index (scores 0–100; scores ≤ 50 indicate low mood and scores ≤ 28 indicate 
likely depression) [19] 
 Hopkins Symptom Checklist 10 measuring psychological distress (score 1–4; scores ≥ 1.85 indicate 
mental distress) [20]. 
 Fatigue Severity Scale. A Norwegian translation of the Fatigue Severity Scale was used (score 9–
63; scores ≥ 36 indicate further evaluation) [21]. 
 Rosenberg Self-Esteem Scale. A validated Norwegian translation of the international 
questionnaire was used (score 10 – 40; values < 25 indicate low self-esteem) [22, 23]. 
 Epworth Sleepiness Scale. A validated Norwegian translation was used (score 0 – 24; normal 0 – 
10; Mild 11 – 14; Moderate 15-18; Severe 19-25) [24]. 
 Sense of humour. A Norwegian version of the short form SHQ-6: “Attitudes toward humour” was 
used (score 6 – 24) [25]. 
Body weight and blood tests were available at inclusion, and before and 12 months after surgery 
for subjects following the scheduled plan. 
Statistics  
The results have been reported as mean (with SD or 95% CI), and number with proportion (in 
percentage). Between groups compaisons were analysed with chi-square tests, t-test, and 
Pearson’s correlation analyses depending on the type of data. Independent predictors of 
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demographics, comorbidity and biochemical biomarkers and APOE status were assessed with 
linear or logistic regression analyses and reported as B-value or Odds Ratio (OR) with 95% 
confidence interval (CI) and p-values. IBM SPSS Statistics for Windows, Version 25.0. Armonk, 
NY: IBM Corp was used for the analyses. P-values < 0.05 were judged as statistically significant. 
The genetic analyses were performed in previously collected blood samples [16-18]. The analyses 
were explorative, and no formal power calculation was performed.  
Results 
Three hundred and fifty Caucasian subjects with morbid obesity were referred to the obesity unit 
during the inclusion period. One hundred and eleven were not included because study nurse was 
unavailable, 80 refused participation, 17 were excluded after erroneous inclusion, and two had 
had to be excluded because they did not fill in the questionnaires. The study included 140 
subjects: men/women 32 (23%)/108 (77%) with mean age 43.0 (SD 8.7) years and BMI 42.1 (SD 
3.8) kg/m2. One hundred and eight and 92 subjects had data on body weight and inflammatory 
markers immediately before bariatric surgery and 12 months after surgery, respectively. 
The prevalence rates of the APOE alleles were: E2E2: 1 (0.7%), E2E3: 13 (9.3%), E2E4: 
4 (2.9%),   E3E3: 71 (50.7%), E3E4: 47 (33.6%), and E4E4: 4 (2.9%) giving prevalence rates of 
the E2, E3, and E4 alleles of 6.8%, 72.1% and 21.1% respectively. The E3 allele was not 
significantly associated with any of the variables in the study (data not shown). 
Demographics and APOE E2 and E4 alleles. 
There was a non-significant trend towards an increased weight reduction in subjects with the E4 
allele after adjusting for age and gender. No other differences in the demographic variables were 
related to the E2 and E4 alleles. Table 1 gives the details. 
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Comorbidity and APOE E2 and E4 alleles. 
Presence of the E2 allele was favourably associated with all the psychosomatic variables (i.e. 
increased well-being and self-esteem, and reduced musculoskeletal pain, psychological distress, 
fatigue and sleepiness). Table 2 gives the details, and figure 1 shows the scores for psychosomatic 
comorbidity in subjects with and without E2 with comparisons between the groups. Presence of 
E2 was furthermore associated with hypertension in the adjusted analyses.  No differences in 
comorbidity were seen between subjects with and without E4. 
Biochemical biomarkers and APOE E2 and E4 alleles. 
CRP was elevated at inclusion, was reduced after conservative induced weight loss, and continued 
to normalise after bariatric surgery. Presence of the E4 allele was associated with lower CRP at all 
points of time. The presence of E2 was associated with high CRP and HbA1c. Table 3 gives the 
details, and figure 2 shows CRP values in subjects with and without E4 at inclusion, after 
conservative treatment and 12 months after surgery. 
Comorbidity and inflammation. 
E2 and E4 were associated with high and low CRP values, respectively. No associations were 
seen between APOE genotype and Il-6 and TNF. Table 4 gives the associations between the 
comorbidities and CRP, E2 and E4 adjusted for age, gender and BMI. The psychosomatic 
comorbidities and hypertension were associated with E2 but not with CRP and E4. Diabetes was 
associated with CRP.   
 
Discussion 
The prevalence rates of the APOE alleles were consistent with those reported in both clinical and 
population-based studies from Scandinavia. [1, 26-28]. The prevalence of E4 might seem high, 
but considering the increasing south-north gradient and comparisons with studies from the same 
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region, the prevalence rates were as expected [28, 29]. The observed distribution of the different 
genotypes was in complete agreement with the predicted genotypes according to Hardy-
Weinberg equilibrium. In a case-control study with 198 obese and normal-weight subjects, the 
prevalence of E4 was high in subjects with obesity [3]. In a review of pooled data from seven 
studies with 27,863 Caucasians, E4 was associated with reduced BMI in individuals above 60 
years of age but not in younger [2]. This study gives no support for an abnormal distribution of 
the E alleles in subjects with morbid obesity but is too small for a valid conclusion. Neither was 
the presence of any of the E alleles significantly associated with weight reduction after 
conservative treatment or bariatric surgery. 
The main finding related to the E4 allele was the significant association with low CRP. 
Similar findings have been reported in previous reports; the relative reduction of CRP has been 
estimated to 34% compared to subjects with zero E4 alleles [30-33]. There was a marked 
reduction of CRP during both treatments periods. The significant differences in CRP between 
subjects with and without the E4 allele persisted at all points of time. The reduction in CRP after 
weight loss was expected because CRP is strongly related to total fat mass, particularly in women, 
and most subjects in this study were women [34].  In the general population, high CRP is an 
independent predictor of cancer-, cardiovascular-, and overall mortality and ischemic stroke [35, 
36]. Therefore, it seems contradictory that E4, which is associated with low CRP, is a predictor of 
cardiovascular disease and mortality, and reduced longevity [1, 37-40]. The same contradiction 
applies to cognitive functions and Alzheimer disease. CRP has been associated with subsequent 
cognitive impairment and age-related cognitive decline, whereas the E4 allele, which was 
associated with low CRP, increases the risk of cognitive reduction and Alzheimer disease [5, 6, 
41, 42]. The interactions between CRP, the APOE genotype, cardiovascular diseases and 
cognitive functions and dementia are confusing and might depend on gender, age, and disease 
such as obesity [43-46]. The association between CRP and atherosclerosis might be diminished in 
subjects with obesity [44]. In this study, after adjusting for age, gender and BMI, the E2 allele was 
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associated with high CRP-values after the two treatment periods and with hypertension. This was 
unexpected since E2 has shown favourable health outcomes such as reduced low-density 
lipoprotein and increased survival [7]. Consequently, using CRP to estimate overall disease risk or 
prognosis may be misleading in subjects with morbid obesity. 
Obesity with comorbidity (hypertension, metabolic syndrome, diabetes) leads to 
cardiovascular disease but protects against the clinical outcome such as short and long term 
mortality rates in subjects with cardiovascular disease [15, 47, 48]. The phenomenon has been 
referred to as the “obesity paradox”. Compared with normal-weight subjects, subjects with 
obesity have an unexplained preservation of vascular function with higher flow-mediated 
dilatation and reduced intima-media thickness [49]. The significance of inflammation on the 
obesity paradox is inconclusive. In one study, body fat protected against mortality in a subgroup 
with high CRP [50]. The association between APOE genotype and coronary disease was 
described as a puzzling paradox in 2006; the paradox is still not solved [51]. There is emerging 
evidence for plasma APOE as a risk factor for dementia, and to a lesser extent for ischemic heart 
disease, but the associations seem to be independent of APOE genotype [52, 53]. A recently 
published study suggests that other genetic factors might contribute to the obesity paradox [54]. 
In this study, the E2 allele was associated with significant or clear trends toward the 
improvement of all the psychosomatic variables: Musculoskeletal pain, WHO-5 Well-Being 
Index, Rosenberg Self-Esteem Scale, Hopkin Symptoms Check-list 10; Epworth Sleepiness Scale, 
and Fatigue. Protection of E2 against depression and reduced vulnerability to psychiatric and 
somatic diseases has also been reported in other studies [8-10]. In all, the E2 allele seems to have 
a range of health-promoting effects. In addition to the psychosomatic effects, E2 has been 
associated with longevity, delayed onset of cognitive decline, reduced LDL-cholesterol and 
reduced overall risk of cardiovascular diseases [1].  
Farup et al. APOE, morbid obesity and comorbidity                                                                                              10 (25) 
 
_____________________________________________________ 
BMC Medical Genetics 
High and low CRP were associated with E2 and E4, respectively. Inflammation has been 
linked to psychosomatic disorders [55-57]. Therefore, post hoc analyses were performed to rule 
out if inflammation could confound the associations between the psychosomatic disorders and 
the APOE alleles. E2 was the only independent predictor of the psychosomatic disorders after 
adjusting for E4, CRP, gender, age and BMI (table 4). CRP was associated with diabetes. These 
results support the reduced importance of CRP as a disease modifier in subjects with obesity [44].  
Strengths and limitation 
Inclusion of consecutive subjects with morbid obesity referred for evaluation of bariatric surgery 
improves the validity of the results. However, since this group is only a minority of all subjects 
with obesity, the transferability of the results to all subjects with obesity is uncertain, and the 
results are not transferrable to subjects with normal weight. The study was too small for valid 
comparisons of the prevalence of the E alleles in subjects with morbid obesity and the general 
population, and for evaluation of the effects of the E alleles on weight loss, but no striking 
differences were observed.  The association between low CRP and E4 observed in this study is in 
accordance with other studies in subjects with and without obesity [30-33]. The lack of 
associations between CRP and comorbidity is known from other studies in subjects with obesity, 
which contrasts to findings in the general population [44]. Favourable effects of E2 have also 
been reported in subjects with other disorders [1, 8-10]. Four subjects with the combination 
E2:E4 were included in two groups, in the group with E4 and the group with E2, and might 
have weakened the analyses.  In all, the consistent findings indicate high external validity of the 
study.  
Conclusions 
The most important finding was the marked improvement of all psychosomatic disorders related 
to the presence of the E2 allele in subjects with morbid obesity. The E2 allele has been ascribed 
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health promoting effects, but the effects seemed more pronounced than in studies in non-obese 
groups. High and low CRP were associated with the E2 and E4 alleles respectively, but not 
associated with obesity-related disorders. The uncertain associations between CRP and 
comorbidity observed in other studies in subjects with obesity seem to imply also to those with 
morbid obesity. No notable effect of the E alleles was observed on BMI or reduction of BMI 
after conservative treatment or bariatric surgery.  
LIST OF ABBREVIATIONS  
BMI: Body Mass Index. CI: Confidence interval. CRP: C-reactive protein. Il-6: Interleukin-6. OR: 
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Table 1. Associations between the subjects’ demographics and APOE E4 and E2 variants. 
 
Subject demographics 





















Gender (female) 43/55 (78%) 65/85 (76%) p=0.84  13/18 (72%) 95/122 (78%) 0.76  
Age (years) 42.6 (9.5) 43.3 (8.1) P=0.68  41.8 (8.4) 43.2 (8.7) 0.53  
Body weight (kg) 124.5 (19.3) 123.3 (18.4) P=0.72  126.2 (20.7) 123.4 (18.4) 0.56  
Height (cm) 171.6 (9.6) 170.7 (8.5) P=0.59  172.2 (9.2) 170.9 (8.9) 0.58  
BMI (kg / m2)  42.1 (4.0) 42.1 (3.7) P=0.99  -0.07 (-1.26;1.13) 
p=0.91 ** 
42.4 (4.9) 42.1 (3.6) 0.73 0.00 (-1.74; 1.74) 
p=1.00 ** 
BMI reduction during the first  
treatment period (no 95) 
3.2 (1.6) 2.9 (1.5) P=0.28 0.34 (-0.21; 0.98) 
p=0.30 
2.7 (1.4) 3.1 (1.6) 0.48 -0.28 (-1.22;0.66) 
P=0.56 
BMI reduction during the last  
treatment period (no 92) 
11.0 (3.7) 10.5 (3.2) P=0.46 0.94 (-0.37;2.25) 
p=0.16 
10.0 (4.5) 10.8 (3.2) 0.44 -0.41 (-2.30;1.48) 
p=0.67 
BMI reduction total (no 92) 14.3 (3.8) 13.4 (3.5) P=0.21 1.36 (-0.04;2.75) 
p=0.057 
12.7 (5.1 ) 13.9 (3.3) 0.45 -0.72 (-2.76;1.32) 
p=0.49 
  
The results are given as mean (SD) or number (proportion). Chi-square and T-test were used for the comparisons. * Adjusted associations between the subject 
demographics (dependent variable) and APOE E4 and E2 variants were analysed with linear regression analyses adjusted for age, gender and BMI and reported as 
unstandardized coefficients (B-value) with 95% confidence intervals and p-values. ** Adjusted for age and gender. 
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Table 2. Associations between comorbidity and APOE E4 and E2 variants 
Subjects’ psychosomatic disorders 

























p=0.51 OR† 0.30 (0.55;3.33) 
p=0.51 
6/18 (33%) 20/117 
(17%) 
0.12 OR† 0.92 (0.77;8.1) 
p=0.12 










0.06 OR† 1.34 (1.21;12.1) 
p=0.022 
Physical activity (no 134) 4.5 (2.3) 4.5 (2.2) p=0.84 - 0.076 (-0.868;0.715) 
p=0.85 
5.1 (1.6) 4.4 (2.3) 0.15 
 
 0.666 (-0.465;1.798) 
p=0.25 
Musculoskeletal pain (no 137) 4.5 (3.0) 4.2 (2.9) p=0.66 -0.21 (-0.81;1.23)  
p=0.68 




WHO-5 Well-Being Index (no139) 58.2 (18.5) 59.8 (17.1) p=0.61 -1.60 (-7.73;4.52)  
p=0.61 




Hopkins Symptom Checklist 10 
(no 135) 
0.62 (0.57) 0.57 (0.53) p=0.58 0.06 (-0.13;0.25)  
p=0.54 




Rosenberg Self-Esteem (no 131) 24.7 (1.9) 24.3 (1.8) p=0.24 0.37 (-0.29;1.02)  
p=0.27 




Fatigue Severity Scale (no 137) 36.6 (15.2) 35.2 (14.6) p=0.61 1.34 (-3.75;6.43)  
p=0.52 




Epworth Sleepiness Scale (no138) 8.9 (5.1) 7.4 (4.3) p=0.06 1.52 (-0.09;3.12)  
p=0.06 




Sense of humour (no 138) 19.6 (2.5) 18.9 (2.8) p=0.12 -0.71 (-0.19;1.60)  
p=0.12 
18.9 (2.5) 19.2 (2.7) 0.70 -0.36 (-1.67;0.96) 
p=0.60 
The results are given as mean (SD) or number (proportion). Chi-square and t-test were used for the comparisons. * Adjusted associations between the subjects’ 
psychosomatic disorders (dependent variable) and APOE E4 and E2 were analysed with linear and logistic regression analyses adjusted for age, gender and BMI. The results 
are reported as unstandardized coefficients (B-value) or †Odds Ratio (OR) with 95% confidence intervals and p-values.  
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Table 3: Associations between biochemical biomarkers and APOE E4 and E2 variants 






















Hb (no 139) 14.6 (1.1) 14.4 (1.1) P=0.23 0.24 (-0.06;0.54) 
P=0.12 
14.6 (1.2) 14.5 (1.1) p=0.57 0.09 (-0.36;0.53) 
p=0.70 
























HbA1C (no 139) 5.9 (1.4) 5.8 (1.3) p=0.62 0.14 (-0.32;0.60) 
p=0.54 




HDL cholesterol (no 139) 1.2 (0.4) 1.2 (0.3) p=0.69 0.03 (-0.08;0.13) 
p=0.64 
1.1 (0.3) 1.2 (0.3) p=0.25 -0.07 (-0.22;0.09) 
p=0.38 
LDL cholesterol (no 139) 3.5 (0.8) 3.3 (0.8) p=0.08 0.25 (-0.04;0.55) 
p=0.09 
3.0 (1.0) 3.4 (0.8) p=0.06 -0.41 (-0.83;0.02) 
p=0.06 
















The results are given as mean (SD). T-test was used for the comparisons. * Adjusted associations between the biochemical biomarkers (dependent variable) and APOE E4 
and E2 were analysed with linear regression analyses adjusted for age, gender and BMI. The results are reported as unstandardized coefficients (B-value) with 95% 
confidence intervals and p-values.  
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Diabetes (no 135) r=0.096 
p=0.27 
OR=1.08 (1.004;1.16) p=0.039 OR=2.42 (0.71;8.21) p=0.157 OR=0.20 (0.72;5.08) p=0.20 
Hypertension (no 135) r=-0.096 
p=0.27 
OR=0.98 (0.92;1.06) p=0.66 OR=4.50 (1.34;15.11) p=0.015 OR=1.15 (0.49;2.73) p=0.76 
Musculoskeletal pain score (no 137) r=-0.134 
P=0.12 
B=-0.07 (-0.15;0.02) p=0.12 B=-1.55 (-3.05;-0.05) p=0.043 B=-0.025 (-1.29;0.78) p=0.63 
WHO-5 Well-Being Index (no139) r=-0.034 
P=0.69 
B=-0.21 (-0.70;0.29) p=0.41 B=13.1 (4.3;22.0) p=0.004  B=-0.53 (-6.7;5.7) p=0.87 
Hopkins Symptom Checklist 10 (no 135) r=0.049 
P=0.57 
B=0.01 (-0.01;0.02) p=0.35 B=-0.37 (-0.64;-0.10) p=0.009 B=0.05 (-0.15;0.24) p=0.64 
Rosenberg Self-Esteem (131) r=0.005 
P=0.96 
B=-0.01 (-0.06;0.05) p=0.77 B=1.01 (0.05;1.98) p=0.040 B=0.44 (-0.24;1.12) p=0.20 
Fatigue Severity Scale (no 137) r=0.021 
p=0.81 
B=0.08 (-0.34;0.50) p=0.71 B=-6.9 (-14.4;0.5) p=0.069 B=0.70 (-4.57;5.97) p=0.79 
Epworth Sleepiness Scale (no138) r=0.019 
P=0.83 
B=0.07 (-0.07;0.20) p=0.33 B=-2.10 (-4.45;0.25) p=0.080 B=1.52 (-0.13;3.17) p=0.071 
Sense of humour (no 138) r=-0.028 
p=0.75 
B=-0.03 (-0.11;0.05) p=0.42 B=-0.31 (-1.47;1.20) p=0.85 B=0.55 (-0.39;1.49) p=0.25 
* The results are given as Pearson’s correlation coefficient (r). † Adjusted associations between the comorbidity (dependent variable) and CRP, E2 and E4, age, gender and 
BMI were analysed with logistic and linear regression analyses. The results are reported as Odds Ratio (OR) and unstandardized coefficients (B-value) with 95% confidence 
intervals and p-values.  
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Figure 1 shows the scores for the psychosomatic disorders in subjects with and without the 
APOE E2 allele. The results are given as mean with 95% CI of the mean. 
 
Figure 2 shows the CRP values in subjects with and without the APOE E4 allele at inclusion, 
before bariatric surgery (i.e. after six months with conservative weight loss) and 12 months after 
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Figure 2 
 
 
 
 
 
